Citation: Hayati F, Nasouti MA, Shayanpour S, Ahmadi Halili S, Nasouti A. Administration of baclofen in end-stage renal disease. J Renal Endocrinol. 2017;3:e02. DOI: 10.15171/jre.2017.02.
Implication for health policy/practice/research/medical education
In individuals with disturbed kidney function and particularly in the patients with end-stage renal disease (ESRD), the accumulation of the drug is occurred and the half-life of the drug is prolonged which can lead to significant side effects and complication including neurological deterioration and coma.